AIBD will help usher in a new era of personalized, patient-centered care.

Inflammatory bowel diseases (IBD), including both Crohn’s disease and ulcerative colitis, cause inflammatory changes in the gastrointestinal tract and can profoundly affect quality of life. 

Patients can have daily gastrointestinal symptoms and fatigue that impact their abilities to carry out day-to-day activities, including school, work, and maintaining relationships with family and friends. Achieving improvement in both bowel inflammation and quality of life is critical.

The 2024 Advances in Inflammatory Bowel Diseases (AIBD) conference will be an unparalleled experience for IBD care professionals, with guidance on patient-centered goals of care. Set for December 9-11 at the Walt Disney World Dolphin Hotel in Orlando, AIBD will offer in-depth discussions on groundbreaking therapies and insightful presentations showcasing the latest advancements and real-world data in the field of IBD treatment.

More than 2,000 attendees will learn from the 75 expert faculty members, 100-plus presentations and 150 research abstracts during the three-day conference.

With multiple therapeutic targets including clinical remission, endoscopic and histologic healing we can lose sight of the patients in front of us who — first and foremost — must improve and maintain their day-day life activities including school, work, personal and family relationships. How do we ensure we’re making the right choices for long-term efficacy and quality of life?

At AIBD, we’ll dive into head-to-head data comparisons, therapeutic drug monitoring, and personalized approaches to help clinicians guide decisions on which treatments can deliver the best outcomes for their patients. Attendees will also learn about emerging therapies on the horizon that could reshape the treatment landscape.

Featured sessions at AIBD, which are sure to spark a healthy debate among faculty presenters and attendees, include:

• Management of Complicated Crohn's Disease, presented by AIBD co-chair Miguel Regueiro, MD, FACG;
• Case Discussion: Accessing Advanced Therapy, with panelists David Choi, PharmD, BCACP; Marina Ivanov, PharmD, BCPS, BCACP; Shubha Bhat, PharmD, MS, FCCP, BCACP; and team leader Jami Kinnucan, MD, AGAF, FACG; and
• Defining Disease Severity in UC — Setting the Stage for Treatment, which I look forward to presenting.

At this pivotal conference, we’ll work together to explore the tools, data and emerging therapies that can help guide us in making these important decisions. AIBD will help usher in a new era of personalized, patient-centered care. 
Gastroenterologists, nurses, physicians, surgeons, and other healthcare professionals who treat IBD patients will want to take part in AIBD, which will provide clinicians the tools they need to stay current in the ever-evolving field of IBD treatment. 

To register for AIBD, hosted in two of the Magic Kingdom’s most luxurious resorts, visit hmpglobalevents.com/aibd.

Let’s navigate this exciting future together! Join us at Advances in IBD and take part in shaping the future of IBD care.

Dr. Millie D. Long is a professor of medicine and director of the gastroenterology and hepatology program at the University of North Carolina at Chapel Hill. Her clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases Center. Dr. Long is a fellow and member of the Board of Trustees of the American College of Gastroenterology and is a 2024 Sherman Prize recipient.